Cormorant Asset Management, LP - Q1 2023 holdings

Add to watchlist

$1.52 Million is the total value of Cormorant Asset Management, LP's 72 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 120.0% .

All
New
Buy
Sell
Exit
Unchanged
 Value Shares↓ Weighting
BuyMOONLAKE IMMUNOTHERAPEUTICSclass a ord$147,422
+131.5%
6,892,101
+13.6%
9.71%
+127.9%
BMEA BuyBIOMEA FUSION INC$110,733
+314.3%
3,570,872
+12.6%
7.29%
+307.7%
AMAM BuyAMBRX BIOPHARMA INCsponsored ads$75,820
+1329.5%
8,500,000
+263.8%
4.99%
+1306.5%
BBIO BuyBRIDGEBIO PHARMA INC$75,562
+624.3%
4,557,414
+232.9%
4.98%
+612.9%
ETNB Buy89BIO INC$42,644
+31.4%
2,800,000
+9.8%
2.81%
+29.3%
NewENLIVEN THERAPEUTICS INC$42,401–1,936,133
+100.0%
2.79%–
PTGX NewPROTAGONIST THERAPEUTICS INC$39,100–1,700,000
+100.0%
2.58%–
PLRX BuyPLIANT THERAPEUTICS INC$38,410
+153.8%
1,444,000
+84.5%
2.53%
+150.0%
BuyIMMUNEERING CORP$23,170
+109.0%
2,386,181
+4.4%
1.53%
+105.7%
VKTX BuyVIKING THERAPEUTICS INC$17,483
+165.7%
1,050,000
+50.0%
1.15%
+161.6%
NewSTRUCTURE THERAPEUTICS INCsponsored ads$13,712–576,373
+100.0%
0.90%–
MORF NewMORPHIC HLDG INC$12,233–325,000
+100.0%
0.81%–
RAPT NewRAPT THERAPEUTICS INC$11,928–650,000
+100.0%
0.79%–
CBAY NewCYMABAY THERAPEUTICS INC$11,087–1,271,429
+100.0%
0.73%–
OLMA BuyOLEMA PHARMACEUTICALS INC$10,695
+109.7%
3,082,000
+48.0%
0.70%
+106.5%
LBPH BuyLONGBOARD PHARMACEUTICALS IN$9,436
+36.6%
2,353,141
+11.1%
0.62%
+34.4%
NewLIANBIOsponsored ads$8,330–4,250,000
+100.0%
0.55%–
ANNX NewANNEXON INC$4,813–1,250,000
+100.0%
0.32%–
FULC NewFULCRUM THERAPEUTICS INC$3,082–1,081,490
+100.0%
0.20%–
EYPT NewEYEPOINT PHARMACEUTICALS INC$662–225,065
+100.0%
0.04%–
LPTX NewLEAP THERAPEUTICS INC$504–1,481,511
+100.0%
0.03%–
NewORCHARD THERAPEUTICS PLCspon ads new$138–25,664
+100.0%
0.01%–
Other managers

Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):

Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2023-05-15
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
QUOTIENT LTD30Q3 20214.3%
ASCENDIS PHARMA A/S30Q4 20224.8%
MINERVA NEUROSCIENCES INC29Q3 20214.4%
ACCELERON PHARMA INC28Q2 20213.4%
OMEROS CORP27Q3 20216.5%
MIRATI THERAPEUTICS INC25Q4 20227.6%
BLUEPRINT MEDICINES CORP25Q3 20213.6%
APELLIS PHARMACEUTICALS INC24Q3 20238.6%
NEUROCRINE BIOSCIENCES INC24Q1 20204.6%
ROCKET PHARMACEUTICALS, INC23Q3 20232.4%

View Cormorant Asset Management, LP's complete holdings history.

Latest significant ownerships (13-D/G)
Cormorant Asset Management, LP Q1 2023 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Ambrx Biopharma Inc.March 13, 202342,771,365-
Altimmune, Inc.February 14, 20232,600,000-
Arcellx, Inc.February 14, 20232,075,000-
BioAtla, Inc.February 14, 20232,499,250-
Eledon Pharmaceuticals, Inc.February 14, 20231,391,663-
GreenLight Biosciences Holdings, PBCFebruary 14, 20234,751,020-
Prometheus Biosciences, Inc.February 14, 2023700,000-
Tango Therapeutics, Inc.February 14, 20231,000,000-
VectivBio Holding AGFebruary 14, 20231,515,087-
Viridian Therapeutics, Inc.\DEFebruary 14, 20231,100,000-

View Cormorant Asset Management, LP's complete significant-ownership history.

Latest filings
TypeFiled
42024-04-22
SC 13G/A2024-04-15
42024-04-03
SC 13G2024-03-21
42024-03-18
SC 13G/A2024-03-18
42024-03-11
13F-HR2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14

View Cormorant Asset Management, LP's complete filings history.

All filings

View complete filings history.

Compare quarters

Export Cormorant Asset Management, LP's holdings

CSVXLS